چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده ثبت کننده مقاله | بهمن اکبری |
| مرحله جاری مقاله | تایید نهایی |
| دانشکده/مرکز مربوطه | دانشکده علوم نوین پزشکی |
| کد مقاله | 58361 |
| عنوان فارسی مقاله | ایمونوتوکسین های نوترکیب به عنوان روشی نوین برای درمان هدفمند سرطان |
| عنوان لاتین مقاله | Recombinant immunotoxins as a new strategy for targeted cancer therapy |
| نوع ارائه | پوستر |
| عنوان کنگره / همایش | 13th International Congress of Immunology & Allergy of Iran |
| نوع کنگره / همایش | پوستر |
| کشور محل برگزاری کنگره/ همایش | ایران - تبریز |
| شهر محل برگزاری کنگره/ همایش | تبریز |
| سال انتشار/ ارائه شمسی | 1395 |
| سال انتشار/ارائه میلادی | 2016 |
| تاریخ شمسی شروع و خاتمه کنگره/همایش | 1395/02/07 الی 1395/02/10 |
| آدرس لینک مقاله/ همایش در شبکه اینترنت | http://isearch.searchcompletion.com/WebSearchResultsCSE.aspx?silvan=1&si=41460&bs=true&tid=2937&q=http%3A%2F%2Fportal-en.tbzmed. |
| آدرس علمی (Affiliation) نویسنده متقاضی | Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran |
| نویسنده | نفر چندم مقاله |
|---|---|
| صفر فرج نیا | اول |
| بهمن اکبری | دوم |
| شیوا عهدی خسروشاهی | چهارم |
| عنوان | متن |
|---|---|
| خلاصه مقاله | Chemotherapy, radiotherapy and surgery are three common conventional treatments for cancer that have had a great successes in treatment, but the mortality rate due to cancer still remained high for several reason. Development of new cancer therapies is based on the design of drugs that targets specifically to cancer cells while have minimal adverse effects on normal tissues. Monoclonal antibodies are among the most specific agents that recognize and bind to cancer cell surface antigens. Despite high successes of monoclonal antibodies, they rarely are able to destroy completely cancer cells alone and it is thought they must be connected to a chemical agents or toxins to increase their efficiency. In immunotoxin based targeted therapy the targeting fragments such as antibodies, ligands and peptides conjugated to toxins, enzymes and other toxic agents. Immunotoxin (ITs) are very efficient so that one ITs molecule enough for killing a tumor cell while 10000- 100000 molecules of chemotherapy needed to kill a tumor cell. ITs according to the type of targeted moiety placed in three groups including: ITs based on the ligand, ITs based on the antibody and based ITs. Today, a variety of ITs have been developed which some of them are in the clinical trials. In 1999 the first IT, Denileukin Diftitox, has been approved by the Food and Drug Administration (FDA) for the treatment of cutaneous T cell lymphoma. In this review, various factors that are considered in construction of ITs as targeted moiety and as the toxic moiety have been discussed. |
| کلمات کلیدی | Cancer therapy, Targeted therapy, Immunotoxin |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| Abstract book first page.jpg | 1395/05/02 | 75230 | دانلود |
| Immunotoxin article. International Congress of Immunology.pdf | 1395/05/18 | 94414 | دانلود |
| Certificat.png | 1395/05/18 | 12236716 | دانلود |
| karbarg.docx | 1395/05/18 | 15819 | دانلود |
| moshakhasate daneshjo.docx | 1395/05/18 | 13366 | دانلود |
